TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00886808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iCo-007 Intravitreal Injection
Description: single dose iCo-007 Intravitreal Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iCo-007 Intravitreal Injection
Description: single dose iCo-007 Intravitreal Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iCo-007 Intravitreal Injection
Description: single dose iCo-007 Intravitreal Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iCo-007 Intravitreal Injection
Description: single dose iCo-007 Intravitreal Injection
Study: NCT00105820

Intervention type: PROCEDURE
Group type: OTHER
Intervention: System level depression care quality improvement
Study: NCT01964859

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous skin fibroblasts
Study: NCT04122807

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac catheter ablation
Description: Cryoablation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac catheter ablation
Description: Cryoablation
Study: NCT01225640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNU-100480
Description: 600 mg twice daily (BID) for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNU-100480
Description: 1200 mg once daily (QD) for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RHZE
Description: Combination tablet (RHZE) dosed by weight. Dosage strength per tablet is 150 mg Rifampicin (R)/75 mg Isoniazid (H)/400 mg Pyrazinamide (Z)/275 mg Ethambutol (E)
Study: NCT02742077

Intervention type: DEVICE
Group type: OTHER
Intervention: Robotic-assisted peripheral vascular intervention
Description: Remote delivery and manipulation of guidewires and rapid exchange catheters during percutaneous vascular interventions.
Study: NCT03201198

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Life
Description: The Active Life intervention focuses on increasing light physical activity (LPA) with 18 sessions over 10 weeks. Each session starts with 20 minutes of walking followed by functional circuit training. The intensity of the exercises and the speed of execution are adjusted to attain a rating of perceived exertion equal to somewhat hard to hard at the end of each circuit. Sessions end with stretching the major muscle groups. Sessions include a behavioral component (self-efficacy enhancing or confidence building) and health education. Subjects are encouraged to increase their total PA by at least 60 minutes a day, focusing on LPA. After completion of the structured intervention subjects will receive 11 5-minute phone coaching sessions and two booster sessions over the next 12 months.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Chair exercises
Description: Chair exercises focus on toning and stretching from a seated position with 18 sessions over 10 weeks. Each session includes 5 minutes of slow stretching, 20 minutes of faster paced exercises, 5 minutes of slower paced stretches, followed by 5-10 minutes of massage and imagery. Guided imagery is used to promote relaxation. Health education includes topics of interest to people with COPD such as basic lung physiology, pathophysiology of COPD, commonly used medications, breathing techniques, healthy eating and physical activity, relaxation, travel considerations, and energy conservation. After completion of the structured intervention subjects will receive 11 5-minute phone coaching sessions and two booster sessions over the next 12 months.
Study: NCT04151017

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous fibrin glue
Description: Conjunctival graft fixation with autologous fibrin glue
Study: NCT04228055

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CLIPP2
Description: Diabetes Prevention Program and Comprehensive Lifestyle Improvement Program with emphasis on a low carbohydrate and Keto diet, physical activity, sleep optimization and stress management.
Study: NCT03923725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine+ Amodiaquine (AL+AQ)
Description: AL: Currently available as dispersible tablets containing 20 mg of artemether and 120 mg of lumefantrine, in a fixed-dose combination formulation. The flavoured dispersible tablet paediatric formulation facilitates use in young children.~The dose of artemether-lumefantrine is administered approaching the WHO-recommended target ranges of artemether 5-24 mg/kg and lumefantrine 29-144 mg/kg over 3 days.~AQ: is available as dispersible tablets of 40 mg. The weight-based treatment schedule aims for a dosage of approximately 10mg (4.5-15mg)/kg/day amodiaquine for three days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine + placebo (AL+PBO)
Description: AL: Currently available as dispersible tablets containing 20 mg of artemether and 120 mg of lumefantrine, in a fixed-dose combination formulation. The flavoured dispersible tablet paediatric formulation facilitates use in young children.~The dose of artemether-lumefantrine is administered approaching the WHO-recommended target ranges of artemether 5-24 mg/kg and lumefantrine 29-144 mg/kg over 3 days.~PBO: Placebo tablets for amodiaquine are identical in size, shape and color to the amodiaquine tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate-mefloquine+piperaquine (AS-MQ+PPQ)
Description: AS: Artesunate will be administered according to an optimised dosing schedule using tablets of 32 or 100 mg artesunate with a dosing target of 4 mg/kg/day.~MQ: Mefloquine will be administered according to an optimised dosing schedule using tablets of 70 or 220 mg mefloquine hydrochloride with a dosing target of 8.3 mg/kg/day.~PPQ: Piperaquine will be administered according to an optimised dosing schedule using tablets of 160 or 500 mg of piperaquine tetraphosphate. The weight-based treatment aims for a dosage of approximately.~* 24 mg/kg/day in patients \<25 kg (range 16.0 - 32.0 mg/kg) piperaquine for three days, thereby approaching the WHO-recommended target range of 20 - 32 mg/kg per day.~* 18 mg/kg/day in patients ≥25 kg (range 15.0 - 29.4 mg/kg) piperaquine for three days, thereby approaching the WHO-recommended target range of 16 - 27 mg/kg per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate-mefloquine+placebo (AS-MQ+PBO)
Description: AS: Artesunate will be administered according to an optimised dosing schedule using tablets of 32 or 100 mg artesunate with a dosing target of 4 mg/kg/day.~MQ: Mefloquine will be administered according to an optimised dosing schedule using tablets of 70 or 220 mg mefloquine hydrochloride with a dosing target of 8.3 mg/kg/day.~PBO: Placebo tablets for piperaquine are identical in size, shape and colour to the piperaquine tablets.
Study: NCT00147355

Intervention type: DRUG
Group type: OTHER
Intervention: ondansetron, ibuprofen, paracetamol
Description: ondansetron 4mg bid + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle

Intervention type: DRUG
Group type: OTHER
Intervention: Ondansetron, ibuprofen, paracetamol
Description: Ondansetron 4mg bid + codeine phosphate 15mg tds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle

Intervention type: DRUG
Group type: OTHER
Intervention: metoclopramide, ibuprofen, paracetamol
Description: metoclopramide 10mg qds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
Study: NCT00570765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic Acid (OCA)
Description: Starting dose of 10 or 50 mg administered orally once daily, followed by dose titration planned from 10 mg to 25 mg to 50 mg once daily, which could be modified for safety and tolerability issues or to achieve adequate therapeutic response.
Study: NCT00147355

Intervention type: DRUG
Group type: OTHER
Intervention: Metoclopramide, codeine phosphate, ibuprofen, paracetamol
Description: metoclopramide 10mg qds + codeine phosphate 15mg tds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
Study: NCT02396979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Holistic Health Recovery Program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Holistic Health Recovery Program
Study: NCT04103671

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prompt panretinal photocoagulation
Description: Study eyes that receive panretinal photocoagulation (prompt PRP eyes at baseline) should have 1200 to1600 burns with a spot size on the retina of approximately 500 microns given over 1 to 3 sittings and completed within 4 weeks of initiation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 25G Pars-plana vitrectomy
Description: Study eyes that receive standard 25G Pars-plana vitrectomy that remove all the vitreous, without laser or Silicone oil tamponade, but filled with perfusion fluid. Surgery should be completed within 4 weeks after randomization.
Study: NCT02709616

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Personalized cellular vaccine
Description: Biological: DC-based cellular vaccine. Subjects will undergo surgical resection and standard 6-week chemo/radiotherapy and cycles of TMZ treatment. They will receive biweekly cellular vaccines.
Study: NCT04232592

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inject a solution of stem cell preparation
Description: The control group was injected with a solution of stem cell preparation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inject stem cells
Description: Three dose groups were designed: low dose group, medium dose group and high dose group.
Study: NCT01921140

Intervention type: DRUG
Group type: OTHER
Intervention: Olaparib tablets
Description: Olaparib dosing (2X 150mg tablets) following allocated meal

Intervention type: DRUG
Group type: OTHER
Intervention: Olaparib tablets
Description: Olaparib dosing (2X 150mg tablets) following allocated meal

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pharmacokinetic sampling
Description: Blood samples taken pre and post dosing with 2x 150 mg olaparib tablet

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pharmacokinetic sampling
Description: Blood samples taken pre and post dosing with 2x 150 mg olaparib tablet

Intervention type: OTHER
Group type: OTHER
Intervention: Dietary Fasted
Description: 2x 150 mg olaparib tablet formulation taken in fasted state. 5-14 days washout period

Intervention type: OTHER
Group type: OTHER
Intervention: Dietary High Fat
Description: 2x 150 mg olaparib tablet formulation taken 30 minutes after allocated meal. 5-14 days washout period.
Study: NCT04151017

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Suture
Description: Graft fixation using 10.0 mononylon
Study: NCT03205917

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGDM1400/Placebo (3mg/kg IV)
Description: 3/1 (6/2 if DLT)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGDM1400/Placebo (10mg/kg IV)
Description: 3/1 (6/2 if DLT)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGDM1400/Placebo (30mg/kg IV)
Description: 3/1 (6/2 if DLT)
Study: NCT00865449

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: spironolactone
Description: 25 mg daily of spironolactone given for 6 months in the peritoneal dialysis patients
Study: NCT03205917

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGDM1400 + PGT121/Placebo (3mg/kg + 3mg/kg IV)
Description: 3/1 (6/2 if DLT)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGDM1400 + PGT121/Placebo (10mg/kg + 10mg/kg IV)
Description: 3/1 (6/2 if DLT);

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGDM1400 + PGT121/Placebo (30mg/kg + 30mg/kg IV)
Description: 3/1 (6/2 if DLT)
Study: NCT00865449

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, given daily for 6 months to Peritoneal Dialysis Patients
Study: NCT04225260

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin neuromodulator
Description: A dose of QM1114-DP will be injected in the GL area and in the LCL area.
Study: NCT03205917

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGDM1400 + PGT121 + VRC07-523LS (20mg/kg + 20mg/kg + 20 mg/kg IV)
Description: 3 (max 9)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGDM1400 + PGT121 (MTD IV)
Description: 3 (max 9)
Study: NCT03744676

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: lisocabtagene maraleucel
Description: lisocabtagene maraleucel will be administered as single dose intravenous (IV) injection
Study: NCT00927823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04691502
Description: Once daily continuous dosing. Dose escalation to Maximally tolerated dose (MTD) until progression or discontinuation.
Study: NCT01149681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APLIDIN (plitidepsin)
Description: Aplidin® (plitidepsin) lyophilized powder and solvent for concentrate for solution for infusion. (2 mg plitidepsin vial and 4 ml ampoule).~Plitidepsin will be administered at 5 mg/m2 intravenously diluted to a total volume of 250 ml in 0.9% saline or 5% dextrose solution on Day 1 and 15 every four weeks for a maximum period of 6 cycles.
Study: NCT00699244

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral placement of local anesthesia
Description: Peripheral placement of local anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Central placement of local anesthesia
Description: Central placement of local anesthesia
Study: NCT02232178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 100mg Xaracoll implants
Study: NCT03480685

Intervention type: DEVICE
Group type: OTHER
Intervention: IVUS and OCT Imaging
Description: Use of an imaging catheter
Study: NCT04612530

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Irreversible Electroporation (IRE)
Description: Irreversible electroporation (IRE) is a local ablative technique that utilizes electrical pulses to destroy tumor tissue

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Irreversible Electroporation (IRE)
Description: Irreversible electroporation (IRE) is a local ablative technique that utilizes electrical pulses to destroy tumor tissue

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab is an immune checkpoint inhibitor targeting the PD-1 receptor on T-cells. Binding of the PD-1 monoclonal antibody onto the PD-1 receptor blocks the brake signal on the T-cells, allowing them to attack the cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is an immune checkpoint inhibitor targeting the PD-1 receptor on T-cells. Binding of the PD-1 monoclonal antibody onto the PD-1 receptor blocks the brake signal on the T-cells, allowing them to attack the cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is an immune checkpoint inhibitor targeting the PD-1 receptor on T-cells. Binding of the PD-1 monoclonal antibody onto the PD-1 receptor blocks the brake signal on the T-cells, allowing them to attack the cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toll-Like Receptor 9
Description: Toll-Like Receptor 9 (CpG) is an oligodeoxynucleotide that stimulates dendritic cells to release IFN type I, activating natural killer and infiltrating T cells. This creates a more pro-immunogenic tumor environment.
Study: NCT00873834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluoxetine
Description: Treatment with fluoxetine in an oral solution will be given at 0.25mg/kg day during 2 weeks and at 0.4mg/kg day during 16 weeks.~A progressive decreased of dosage on a period of 4 weeks to 0.25mg/kg/day (2 weeks) and 0.10mg/kg/day(2 weeks) will be realized
Study: NCT03095339

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational package
Description: The educational package was offered to 30 villages post randomization. The field team completed the SARAR PHAST with community members for 2-3 days in each intervention village. The movie was projected every night for 2-3 days in each intervention village.
Study: NCT02232178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 100mg Xaracoll implants

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 150mg Bupivacaine HCl injection
Study: NCT04037735

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ATTUNE S+ Knee Prosthesis by DePuy
Description: Total Knee Replacement (TKR) Surgery with ATTUNE S+ Knee Prosthesis by DePuy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PFC Sigma Knee Prosthesis by DePuy
Description: Total Knee Replacement Surgery with PFC Sigma Knee Prosthesis by DePuy
Study: NCT00957086

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nimotuzumab
Description: Administered by intravenous infusion at 200 mg absolute per dose, diluted in 250 ml of sodium chloride over 30 minutes. 8 weekly doses of study drug will be given, beginning on first week of radiotherapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by intravenous infusion at 200 mg absolute per dose, diluted in 250 ml of sodium chloride over 30 minutes. 8 weekly doses of study drug will be given, beginning on first week of radiotherapy.
Study: NCT03357341

Intervention type: DEVICE
Intervention: Mobile spirometer
Description: Mobile spirometer will be used to measure FEV1 values weekly.

Intervention type: DEVICE
Intervention: Mobile spirometer
Description: Mobile spirometer will be used to measure FEV1 values weekly.

Intervention type: DEVICE
Intervention: Device sensor
Description: Sensors will be attached to rescue and maintenance inhalers to measure use of rescue medication and maintenance therapy.

Intervention type: DEVICE
Intervention: Device sensor
Description: Sensors will be attached to rescue and maintenance inhalers to measure use of rescue medication and maintenance therapy.

Intervention type: DRUG
Intervention: Salbutamol
Description: Salbutamol MDI will be given as a rescue medication to be used on an as needed basis in this study.

Intervention type: DRUG
Intervention: Salbutamol
Description: Salbutamol MDI will be given as a rescue medication to be used on an as needed basis in this study.

Intervention type: DEVICE
Intervention: Activity monitor
Description: Subjects will be required to wear activity monitors daily to record their physical activity.
Study: NCT00873834

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo comparator. The packaging of study drug and placebo will be performed according to applicable regulatory requirements in the same packaging. An oral solution will be administrated.
Study: NCT00808717

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 10 mg vs. 80 mg before intervention
Study: NCT03762122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rogaratinib
Description: Rogaratinib (BAY 1163877; Bayer) is an oral pan-kinase inhibitor, which selectively inhibits FGFR1, FGFR2, FGFR3, and FGFR4.
Study: NCT00114101

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous PBSCT

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous PBSCT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study: NCT02210546

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)

Intervention type: OTHER
Group type: OTHER
Intervention: Mammography (Mx) + ultrasonography (US)
Study: NCT01570088

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic acid
Description: One roll/bun per day fortified with 400 µg of folic acid

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-5-MTHF
Description: One roll/bun per day fortified with 452 µg of L-5-MTHF

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains no folic acids
Study: NCT02802943

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide Vaccine
Description: Individualized multi-peptide cocktail consisting of 300 μg each of 5 HLA class I and 4 HLA class II restricted peptides. The peptides for each individual patient will be selected from a warehouse consisting of 30 different peptides restricted by the 6 most common HLA class I allotypes (A\*01, A\*02, A\*03, A\*24, B\*07, B\*08) and 4 HLA class II peptides. Peptides will be administered subcutaneously. Vaccination will take place on d1, d4, d8, d15, d22 followed by vaccinations every 4 weeks for 1 year. The peptide warehouse is selected based on our data on the non-mutant HLA-presented antigenome of CLL identified as frequently presented CLL-associated T cell epitopes with a high potential for broad clinical application.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide Vaccine
Description: Individualized multi-peptide cocktail consisting of 300 μg each of 5 HLA class I and 4 HLA class II restricted peptides. The peptides for each individual patient will be selected from a warehouse consisting of 30 different peptides restricted by the 6 most common HLA class I allotypes (A\*01, A\*02, A\*03, A\*24, B\*07, B\*08) and 4 HLA class II peptides. Peptides will be administered subcutaneously. Vaccination will take place on d1, d4, d8, d15, d22 followed by vaccinations every 4 weeks for 1 year. The peptide warehouse is selected based on our data on the non-mutant HLA-presented antigenome of CLL identified as frequently presented CLL-associated T cell epitopes with a high potential for broad clinical application.
Study: NCT03357341

Intervention type: DEVICE
Intervention: Activity monitor
Description: Subjects will be required to wear activity monitors daily to record their physical activity.
Study: NCT02802943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: All patients will receive imiquimod (Aldara®) as local adjuvant, applied topically at the side of vaccination 18h to 24h prior to the vaccination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: All patients will receive imiquimod (Aldara®) as local adjuvant, applied topically at the side of vaccination 18h to 24h prior to the vaccination.